Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study

Authors
Publication date
1 January 2015
Publisher
eScholarship, University of California

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Sustaining member

    eScholarship - University of California

    redirect
    oaioai:escholarship.org:ark:/1303...
    Last time updated on 25/12/2021